Philadelphia Biotech Firm to Present Gene Therapy Research

Latus Bio will unveil four preclinical research posters at an annual gene therapy conference in Germany later this month.

Updated on Oct. 25, 2026 in Biotech

Philadelphia Biotech Firm to Present Gene Therapy Research

Live Poll

Do you believe gene therapy advancements will significantly improve treatment outcomes for complex diseases?

Philadelphia-based Latus Bio is set to share findings from its gene therapy research at the European Society of Gene and Cell Therapy's 33rd Annual Congress. The conference will take place from October 27-30, 2026, in Hamburg, Germany.

Why it matters

This research provides insights into gene delivery technologies designed to address genetic conditions affecting the brain and nervous system. The studies focus on specific therapies to manage Huntington's disease and CLN2 Batten disease by targeting cellular deficiencies.

The company will showcase data on the LTS-201 therapy, which uses an AAV-DB-3 capsid and microRNA to lower MSH3 expression. Additionally, they will present on LTS-101, an AAV-Ep+ capsid-based gene therapy designed to deliver the human TPP1 gene.

The players

Latus Bio

This Philadelphia-based biotechnology firm focuses on developing advanced gene therapies for severe neurological and systemic genetic diseases.

European Society of Gene and Cell Therapy

This professional scientific organization hosts annual congresses to share major breakthroughs in genetic and cellular research.

The details

Latus Bio specializes in delivery technologies for genetic treatments that reach brain, spinal cord, and kidney cells. Their current research aims to mitigate somatic instability in Huntington's disease and restore genetic function in CLN2 Batten disease patients.

The 33rd Annual Congress runs from October 27-30, 2026.
Data on the LTS-101 therapy for CLN2 Batten disease will be presented on October 28, 2026.
Research regarding LTS-201 and AAV capsid developments is scheduled for October 29, 2026.

The Tech Race

This work extends ongoing efforts to refine AAV-based gene therapy delivery vectors for treating complex neurodegenerative diseases. By testing various capsid variants, the firm positions itself within the competitive landscape of next-generation genetic medicine.

While these therapies remain in preclinical stages, the advancement of these delivery methods could eventually offer new treatment options for patients with rare genetic disorders. Success in these trials would represent a milestone in managing previously incurable conditions.

The takeaway

Advancements in AAV capsid engineering continue to be a primary driver for the evolution of gene therapy treatments. Future research will likely focus on transitioning these laboratory findings into clinical trials to prove safety and efficacy in patients.